Robert M. Knabb
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Blood Coagulation and Thrombosis Mechanisms, Atrial Fibrillation Management and Outcomes, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Venous Thromboembolism Diagnosis and Management, Protease and Inhibitor Mechanisms
Most-Cited Works
- → Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients(2011)542 cited
- → Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa(2007)391 cited
- → Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies(2008)299 cited
- → The selective inhibition of thrombin by peptides of boroarginine.(1990)253 cited
- → Discovery of 1-(3‘-Aminobenzisoxazol-5‘-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2‘-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide Hydrochloride (Razaxaban), a Highly Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor(2004)188 cited